Domestic innovative drugs, science and technology innovation to finance 2 billion!

The pharmaceutical industry is one of the key development and management industries in China in recent years The development of the industry is regulated and influenced by the relevant national policies With the continuous promotion of the joint reform of medicine, medical treatment and medical insurance, the pilot implementation of two vote system and other industrial policies has brought new development opportunities and challenges to the medical industry Cutting edge biology resumed its inquiry on the science and technology innovation board late yesterday, and its product iconine broke the monopoly of foreign pharmaceutical companies on new AIDS drugs and established China's innovation capability in this field Founded in 2013, frontier biology, a scientific research achievement breaking the monopoly of foreign countries, is an innovative biomedical enterprise based in China and facing the world, with international competitiveness It is committed to research, development, production and sales of innovative drugs for unmet major clinical needs The innovative anti HIV technology of cutting-edge biology belongs to the international leading level and has global competitiveness Frontier biology focuses on the research and development of new drugs in the field of long-acting polypeptides, and focuses on differentiated product development strategies for unmet clinical and patient needs The core products are national class I new drugs, China's first original new drug for the treatment of HIV, and the world's first long-term HIV fusion inhibitor, Ai Bove Tai (trade name "aikening") It is the only approved long-term anti HIV injection drug in the Chinese market It is given once a week, and combined with other anti HIV drugs, it can quickly and effectively suppress the virus and improve the immune ability At the same time, it fills in the clinical blank of AIDS treatment program for hospitalized and severe patients in China, which has certain clinical irreplaceable, and meets some major clinical needs in the field of public health Aikonin has also broken the monopoly of foreign pharmaceutical companies in fighting AIDS new drugs and established China's innovation ability in this field However, because aikonin is still in the initial stage of commercialization, the recognition of aikonin in the domestic market still needs to be cultivated In 2018 and January March 2019, the production and marketing rates of the company's main products, iconine, were 14.02% and 22.98% respectively With single revenue and high cost performance, leading edge biology has one original anti AIDS drug that has been listed and patented in major global markets, and two new drugs in research that are in phase II clinical stage in the United States, have obtained patents (or patent licenses) and have clear clinical efficacy Figure: aikoning, a floor welding production line built by the issuer, is a national first-class new drug independently researched and developed by the company It has achieved technological breakthroughs in molecular structure, polypeptide sequence and chemical modification, action target and distribution and metabolism in the human body It has played a synergistic role with other antiviral drugs to achieve external resistance and internal inhibition and mechanism complementarity At the same time, it has great advantages in drug mechanism, patient compliance, safety and treatment costs Compared with large pharmaceutical enterprises at home and abroad, the product structure is not rich enough, and the performance is limited by the development of a single product in the short term The main product iconine began to be sold in August 2018 Since then, the company has realized the main business income and is the only main business income source of the company The pharmaceutical industry is high-tech, high-risk and high investment In general, the whole process of drug from research and development, clinical trial, trial production, industrialization of scientific research results to final product sales has to go through many approvals and tests, which costs a lot of time and money Frontier biology also faces such problems: the company's product pipeline combination therapy and Ab001 are both in the R & D stage, requiring a large amount of R & D investment During the reporting period, the company lost money and had a large amount of uncovered losses As of March 31, 2019, the company's accumulated uncovered losses were 428 million yuan Meanwhile, the R & D investment is very high During the reporting period, the R & D investment of the company is 54.7623 million yuan, 83.5543 million yuan, 99.4377 million yuan and 2012.23 million yuan respectively Penicillin is the reprinted content of yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.